For example, pro-inflammatory cytokines in the tumor microenvironment (e.g., IL-6, TNF-α, and IL-1β) can activate signaling pathways (e.g., NF-κB and STAT3) that promote tumor cell proliferation, invasive capacity, and resistance to therapy. This evidence concerns the gene NFKB1 and neoplasm.